Yet another new drug can temporarily hold off the mental decline caused by Alzheimer’s disease, scientists say.
The drug, called donanemab, slowed cognitive decline by about 35 percent over the course of a year and a half, according to data presented July 17 at the Alzheimer’s Association International Conference in Amsterdam and published the same day in JAMA.
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.